Publications by authors named "Per Brunmark"
Article Synopsis
- Atypical antipsychotic drugs (APDs) target dopamine D(2) receptors but have side effects like motor deficits and cognitive dulling; newer APDs with additional effects on serotonin receptors (5-HT(2A)) show better efficacy.
- ACP-103 is a novel compound that acts as a selective 5-HT(2A) inverse agonist without affecting D(2) receptors, aiming to enhance therapeutic effects while minimizing side effects.
- Research indicates that ACP-103 can improve the effectiveness of other APDs and reduce unwanted side effects associated with them, suggesting its potential as a beneficial adjunctive treatment.
The pulmonary absorption of nine low-molecular-weight (225-430 Da) drugs (atenolol, budesonide, enalaprilat, enalapril, formoterol, losartan, metoprolol, propranolol and terbutaline) and one high-molecular-weight membrane permeability marker compound (FITC-dextran 10000 Da) was investigated using the isolated, perfused and ventilated rat lung (IPL). The relationships between pulmonary transport characteristics, epithelial permeability of Caco-2 cell monolayers and drug physicochemical properties were evaluated using multivariate data analysis. Finally, an in vitro-in vivo correlation was made using in vivo rat lung absorption data.
View Article and Find Full Text PDFThe airway-to-blood absorption of the mu-selective opioid tetrapeptide agonist Tyr-D-Arg-Phe-Phe-NH(2) (MW 631) was investigated in the isolated, perfused, and ventilated rat lung model. The lung metabolism of the peptide was compared after airway and vascular delivery. The concentrations of the parent tetrapeptide and five of its metabolites in the perfusate and in bronchoalveolar lavage fluid were analyzed by LC-MS.
View Article and Find Full Text PDF